EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Development of Petrelintide: a Potent, Stable, Long-Acting Human Amylin Analogue

Henrik Fischer Munch iD, Rasmus Just, Jesper Mosolff Mathiesen, Per-Olof Eriksson, Jesper Skodborg Villadsen, Bill Vestergaard, Maria Deryabina, Oliver Demmer, Jolanta Skarbaliene, Dieter W Hamprecht iD, Wolfgang Rist, Tamara Baader-Pagler und 3 weitere

Journal of Medicinal Chemistry · 27.11.2025 · 68 (22) · 23925-23940

DOI: 10.1021/acs.jmedchem.5c01185 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 11.11.2025. Verfasst von Henrik Fischer Munch und 14 weiteren Autor:innen. Beteiligte Einrichtung: Zealand Pharma A/S, 2860 Søborg, Denmark. Hauptthemen laut MEDLINE: Islet Amyloid Polypeptide. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Zealand Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The past few years have seen the approval of several medications for weight management, but there is an increasing need for new therapies that target different pathways of energy balance. Owing to its role as a physiological satiety signal released after nutrient intake, amylin is an attractive pharmacological target for weight management in individuals living with obesity. Furthermore, combinations of peptide drugs for weight management may be more effective than individual peptide drugs. Thus, there is a need for peptide drugs that potentially also can be used as combination therapies, to enable coformulation with currently marketed drugs. Herein, we report the development of petrelintide, a potent, stable, long-acting analogue of human amylin that can be formulated at about neutral pH. This was enabled through optimization of chemical stability while retaining in vitro and in vivo potency. Petrelintide is in clinical development as a potential treatment for weight management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Islet Amyloid PolypeptideHumansAnimalsMaleDrug StabilityMiceRats

Substanzen

Islet Amyloid Polypeptide

Autor:innen und Institutionen

  • Zealand Pharma A/S, 2860 Søborg, Denmark.
  • Boehringer Ingelheim Research Italy, 24040 Milan, Italy.
  • Boehringer Ingelheim Pharma GmbH & Co. KG, 55218 Ingelheim am Rhein, Germany.

ORCID-Profile: Henrik Fischer Munch, Dieter W Hamprecht

Förderung

  • Zealand Pharma

Zitieren

APA

Fischer Munch, H., Just, R., Mosolff Mathiesen, J., Eriksson, P. O., Skodborg Villadsen, J., Vestergaard, B., Deryabina, M., Demmer, O., Skarbaliene, J., Hamprecht, D. W., Rist, W., Baader-Pagler, T., Grube, A., Heim-Riether, A., & Giehm, L. (2025). Development of Petrelintide: a Potent, Stable, Long-Acting Human Amylin Analogue. Journal of Medicinal Chemistry, 68(22), 23925-23940. https://doi.org/10.1021/acs.jmedchem.5c01185

Vancouver

Fischer Munch H, Just R, Mosolff Mathiesen J, Eriksson PO, Skodborg Villadsen J, Vestergaard B, et al. Development of Petrelintide: a Potent, Stable, Long-Acting Human Amylin Analogue. Journal of Medicinal Chemistry. 2025;68(22):23925-23940. doi:10.1021/acs.jmedchem.5c01185

BibTeX
@article{FischerMunch2025,
  author = {Fischer Munch, Henrik and Just, Rasmus and Mosolff Mathiesen, Jesper and Eriksson, Per-Olof and Skodborg Villadsen, Jesper and Vestergaard, Bill and Deryabina, Maria and Demmer, Oliver and Skarbaliene, Jolanta and Hamprecht, Dieter W and Rist, Wolfgang and Baader-Pagler, Tamara and Grube, Achim and Heim-Riether, Alexander and Giehm, Lise},
  title = {Development of Petrelintide: a Potent, Stable, Long-Acting Human Amylin Analogue},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  volume = {68},
  number = {22},
  pages = {23925--23940},
  doi = {10.1021/acs.jmedchem.5c01185}
}
Kostenlos starten →